Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORMP | US
0.04
1.05%
Healthcare
Biotechnology
30/06/2024
16/04/2026
3.86
3.78
3.89
3.75
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2 an orally ingestible insulin capsule which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801 Phase 2 oral insulin capsule for non-alcoholic steatohepatitis a progressive liver diseases; and ORMD-0901 an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
View LessPositive Momentum
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
36.4%1 month
41.9%3 months
52.4%6 months
52.9%4.54
-
0.53
-
-
0.52
2.86
-
-12.65M
157.37M
157.37M
-
-
-
-100.00
12.70
3.47
0.92
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.60
Range1M
0.68
Range3M
0.78
Rel. volume
0.90
Price X volume
341.17K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CABALETTA BIO INC. | CABA | Biotechnology | 3.52 | 171.95M | 3.53% | n/a | 3.71% |
| Centrexion Therapeutics Corporation | CNTX | Biotechnology | 2.29 | 171.75M | -8.76% | n/a | 0.00% |
| Adagene Inc. | ADAG | Biotechnology | 3.85 | 170.44M | 0.79% | n/a | 36.29% |
| Protalix BioTherapeutics Inc | PLX | Biotechnology | 2.3 | 169.15M | -3.36% | n/a | 91.50% |
| OBIO | OBIO | Biotechnology | 4.47 | 169.08M | -2.19% | n/a | 3.29% |
| Vaxart Inc | VXRT | Biotechnology | 0.728 | 165.58M | -0.21% | n/a | 28.91% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 5.16 | 165.56M | 0.19% | n/a | -186.13% |
| Connect Biopharma Holdings Limited American Depositary Shares | CNTB | Biotechnology | 2.99 | 165.21M | 2.05% | n/a | 0.29% |
| Achieve Life Sciences Inc | ACHV | Biotechnology | 4.81 | 165.18M | 35.49% | n/a | 41.73% |
| Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 5.57 | 165.17M | -3.13% | n/a | 6.50% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.74 | 156.39M | 0.72% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.99 | 100.48M | 0.63% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.12 | 99.69M | 0.49% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.93 | 74.70M | 1.14% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.32 | 59.96M | 0.00% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 14 | 21.32M | 2.04% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.612 | 11.83M | -2.84% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.74 | 10.81M | 6.52% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.335 | 3.41M | -2.06% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2167 | 2.06M | -6.19% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.52 | 0.53 | Par |
| Ent. to Revenue | 2.86 | 3,967.00 | Cheaper |
| PE Ratio | 4.54 | 41.03 | Cheaper |
| Price to Book | 0.53 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 52.45 | 72.80 | Lower Risk |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 157.37M | 3.66B | Emerging |